Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development

Citation for published version:

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Early version, also known as pre-print

Published In:
Journal of Bone and Mineral Research

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development of the chick

Vicky E. MacRae1,*, Megan G. Davey1,*, Lynn McTeir1, Sonoko Narisawa2, Manisha C. Yadav2, Jose Luis Millan2, and Colin. Farquharson1

1Division of Developmental Biology, The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Roslin Biocentre, Roslin, UK

2Sanford Children’s Health Research Center, Burnham Institute for Medical Research, La Jolla, CA 92037, USA.

Abstract

PHOSPHO1 is a bone specific phosphatase implicated in the initiation of inorganic phosphate generation for matrix mineralization. The control of mineralization is attributed to the actions of tissue-non specific alkaline phosphatase (TNAP). However, matrix vesicles (MVs) containing apatite crystals are present in patients with hypophosphatasia as well as TNAP null (Akp2−/−) mice. It is therefore likely that other phosphatases work with TNAP to regulate matrix mineralization. Although PHOSPHO1 and TNAP expression is associated with MVs, it is not known if PHOSPHO1 and TNAP are co-expressed during the early stages of limb development. Furthermore the functional in-vivo role of PHOSPHO1 in matrix mineralization has yet to be established. Here, we studied the temporal expression and functional role of PHOSPHO1 within chick limb bud mesenchymal micromass cultures and also in wild-type and talpid3 chick mutants. These mutants are characterized by defective hedgehog signalling and the absence of endochondral mineralization. The ability of in-vitro micromass cultures to differentiate and mineralize their matrix was temporally associated with increased expression of PHOSPHO1 and TNAP. Comparable changes in expression were noted in developing embryonic legs (developmental stages 23–36HH). Micromass cultures treated with lansoprazole, a small-molecule inhibitor of PHOSPHO1 activity, or FGF2, an inhibitor of chondrocyte differentiation, resulted in reduced alizarin red staining (P<0.05). FGF2 treatment also caused a reduction in PHOSPHO1 (P<0.001) and TNAP (P<0.001) expression. Expression analysis by whole mount RNA in-situ hybridization, correlated with qPCR micromass data and demonstrated the existence of a tightly regulated pattern of Phospho1 and Tnap expression which precedes mineralization. Treatment of developing embryos for 5-days with lansoprazole completely inhibited mineralization of all leg and wing long bones as assessed by alcian blue/alizarin red staining. Furthermore, long bones of the talpid3 chick mutant did not express Phospho1 or Tnap whereas flat bones mineralized normally and expressed both phosphatases. In conclusion, this study has disclosed that PHOSPHO1 expression mirrors that of TNAP during embryonic bone development and that PHOSPHO1 contributes to bone mineralization in developing chick long bones.

© 2009 Elsevier Inc. All rights reserved.

Address for Correspondence Dr Colin Farquharson The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Roslin Biocentre, Roslin, UK. Tel: 44 (0)131 527 4399. Fax 44 (0) 131 440 0434. colin.farquharson@roslin.ed.ac.uk. Both authors contributed equally to this work

Publisher’s Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Introduction

During the process of endochondral bone formation, chondrocytes and osteoblasts mineralize their extracellular matrix by promoting the initial formation of crystalline hydroxyapatite (HA) in the sheltered interior of membrane-limited matrix vesicles (MVs) [1]. This is followed by the modulation of matrix composition to further promote propagation of apatite outside of the MVs [2,3]. This biphasic two-step mineralization process depends on a regulated balance of a number of factors such as calcium and inorganic phosphate (P$_i$) concentrations, the presence of matrix proteins, and the presence of mineralization inhibitors such as inorganic pyrophosphate (PP$_i$), matrix gla protein, and osteopontin [4-6]. Three osteoblast molecules have been identified as affecting the controlled deposition of bone mineral by regulating the extracellular levels of PP$_i$, and in turn, of osteopontin: tissue-non specific alkaline phosphatase (TNAP), ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) and the ankylosis protein (ANK) [7-11].

In bone, TNAP is confined to the cell surface of osteoblasts and chondrocytes, including the membranes of their shed MVs [12]. It has been proposed that in bone matrix, TNAP generates P$_i$ for HA crystallization [13,14]. However, TNAP also hydrolyzes PP$_i$ to facilitate mineral precipitation and growth [15,16]. A variety of loss-of-function mutations in the human TNAP gene (ALPL) lead to hypophosphatasia, an inborn error-of-metabolism characterized by rickets and osteomalacia [17]. Mice with null mutations in the orthologous Akp2 gene phenocopy infantile hypophosphatasia [18], showing elevations in the known substrates of TNAP (pyridoxal-5’-phosphate and PP$_i$). However, critical examination of Akp2$^{-/-}$ mice clearly show that they are born with a mineralized skeleton and still contain HA crystals inside their MVs [19]. It is therefore likely that another enzyme is responsible for either cleaving PP$_i$ or elevating the intra-vesicular concentration of P$_i$ so as to achieve a P$_i$/PP$_i$ ratio conducive for crystallization. We have recently proposed that PHOSPHO1 may fulfil this role [20-23].

Sequence analysis and mutagenesis studies have confirmed PHOSPHO1 as a member of the haloacid dehalogenase superfamily of hydrolases, and that its expression is restricted to sites of mineralization in both cartilage and bone in the adult including MVs [20,23]. PHOSPHO1 is a soluble cytosolic enzyme that has specificity for phosphoethanolamine (PEA) and phosphocholine (PCho) [21-24]. Both PEA and PCho are the two most abundant phosphomonoesters in cartilage [25] and this has led us to hypothesize that PHOSPHO1 is responsible for generating P$_i$ for skeletal mineralization through its highly specific phosphohydrolase activity. Direct functional evidence for this was obtained using the PHOSPHO1-specific inhibitors SCH 202676 and lansoprazole. Lansoprazole was recently identified as a PHOSPHO1-specific inhibitor using high-throughput screening of commercially available chemical libraries. Its ability to pharmacologically inhibit the first step of MV-mediated mineralization has been confirmed, with lansoprazole decreasing the amount of liberated P$_i$ from isolated chick MVs by 28% and from murine TNAP-null MVs by 57% [23]. Expression analysis in the developing chick embryonic skeleton has further indicated that PHOSPHO1 expression occurs in the diaphysis of long bones in developing embryos consistent with a role for PHOSPHO1 in the initial stages of mineral formation [21].

TNAP activity is known to correlate with bone formation in the developing chick limb [26]. Subsequent studies have postulated that increased TNAP activity is associated with osteogenic expression and that enzyme activity is first detected by stage 28HH where it is confined to the
perichondrium. This is before the first evidence for mineral deposition in the periosteal osteoid at stage 32/33HH [27,28]. It is unknown if PHOSPHO1 is likewise expressed during the early developmental stages of limb bud development and in particular if it has a role in the mineralization of the primitive cartilage template laid down after mesenchymal cell differentiation and chondrogenesis. Furthermore it is not known if PHOSPHO1 and TNAP are co-expressed during developmental bone mineralization as would be predicted from their complementary functions during mineralization. Therefore, using the chick model, the aim of this study was to determine if PHOSPHO1 has a functional role in mineralization during limb development and further, to provide fundamental insights into the expression profiles of both PHOSPHO1 and TNAP during limb bud mesenchymal cell differentiation.

**Material and Methods**

**Embryo collection**

Fertilized eggs from White Leghorn, or *talpid* flocks maintained at The Roslin Institute were incubated at 38°C and assessed by developmental stage as per Hamburger and Hamilton [29]. Long bone formation during chick development has been well characterized [29,30] where chondrogenesis of the humerus, radius, ulna,ibia and fibula starts at day 6 (29HH) and ossification starts 1 day later (31HH). Development of the femur is slightly advanced where chondrification is noted by day 5 (27HH) and ossification on day 6 (29HH). Ossification of the long bones of the wing and leg are well developed by day 11 (37HH). All animal studies were approved by The Roslin Institute’s Animal Users’ Committee.

**Micromass cell culture**

Leg limb buds were dissected from stage 23HH wild-type embryos in cold PBS and treated with 10X trypsin (Sigma, Poole, Dorset, UK) on ice for 35min. The ectoderm was removed and limb buds dissociated by gentle pipetting. The single cell suspension was resuspended in growth medium (DMEM/Ham’s F12 (Invitrogen, Paisley, UK) supplemented with 10% FBS (Invitrogen), 1% PSF (Invitrogen), 10 mM β-glycerophosphate (Sigma), 50 μg/ml ascorbic acid (Sigma) and 1% L-glutamine (Invitrogen)) at a density of 2.0 × 10⁷/ml and spotted in 10μl droplets per well of 4-well tissue culture plates (Thermo Fisher Scientific, Roskilde, Denmark) for 45min at 37°C before wells were flooded with 500μl of growth medium. Recombinant human FGF2 (Invitrogen) at 50ng/ml was added to cultures on the day of plating. Lansoprazole (Sigma) at 100μM in 0.1% DMSO was added on the day of plating for 3 or 7-days. Control cultures received 0.1% DMSO only.

**Chondrocyte matrix production**

Collagen deposition was evaluated by staining the cell layers with sirius red dye reagent (Biocolor Ltd., Newtonabbey, UK) [31]. Cells were washed twice with PBS and fixed in 4% paraformaldehyde for 5 min at 4°C, washed extensively in distilled water, and plates were left to air dry before staining for 1hr with sirius red. Cell layers were washed extensively with distilled water, followed by 0.001M hydrochloric acid to remove unbound dye. Stained cell layers were digested with 0.1M sodium hydroxide for 30 min and the optical density (O.D) of the digests was measured at 570nm by spectrophotometry (Multiskan Ascent, Thermo Electron Corporation, Vantaa, Finland). Proteoglycan synthesis was evaluated by staining the cell layers with alcian blue [32]. Cells were washed twice with PBS, fixed in 95% methanol for 20 min and stained with 1% alcian blue 8GX (Sigma) in 0.1M HCL overnight and rinsed with distilled water. Alcian blue-stained cultures were extracted with 1ml 6M guanidine-HCL for 6hr at room temperature and the O.D was determined at 630nm by spectrophotometry.
**Chondrocyte matrix mineralization**

Calcium deposition was evaluated by staining cell layers with alizarin red [33,34]. Cells were washed twice with PBS, fixed in 4% paraformaldehyde for 5 min at 4°C, stained with 2% alizarin red (pH 4.2) for 5 min at room temperature and rinsed with distilled water. Alizarin red-stained cultures were extracted with 10% cetylpyridium chloride for 10 min and the O.D. was determined at 570nm by spectrophotometry.

**Semi-quantitative gene expression**

RNA was extracted from cultured cells and developing leg tissue from stages 23-36HH using RNeasy total RNA (Qiagen Ltd, Crawley, West Sussex, UK), according to the manufacturer’s instructions. For each sample, total RNA content was assessed by absorbance at 260nm and purity by A260/A280 ratios. RNA was reverse transcribed and the PCR reaction undertaken as described previously [35]. For the PCR reaction, primers for 18S (20 cycles, 488bp) (Ambion, Huntingdon, Cambs, UK, sequence unknown), collagen type II (30 cycles, 172bp, forward 5′CAC ACT GGT AAG TGG GGC AAG ACC3′, reverse 5′GGA TTG TGT TGT TTC AGG GTT CGGG3′) and collagen type X (20 cycles, 398bp, forward 5′GGA GAG TCT AGA GAA CTA CTA GG3′, reverse 5′ATTCTGAATTCGGCAGCTGGAGC3′) were used. The number of cycles performed was titrated to ensure that the reactions were in the exponential phase. Reaction products were analysed on 1.5% agarose gels in the presence of ethidium bromide (250μg/L), and a digital image of each gel was captured using a gel documentation system (Bio-Rad Laboratories, Inc., Hemel Hempstead, Herts, UK).

**Lactate dehydrogenase activity**

Lactate dehydrogenase (LDH) activity was determined in the culture medium of 7-day old control and lansoprazole treated micromass cultures using a kit from Roche Diagnostics (Lewes, East Sussex, UK). LDH activity was related to the protein content of the cell pellet as determined using standard procedures.

**Quantitative gene expression**

RNA was extracted from cultured cells and developing leg tissue stages 23-36HH, quantified and reverse transcribed as described above. RT-qPCR was performed using the Stratagene Mx3000P real-time QPCR system (Stratagene, CA, USA). Primers were designed to span at least one intron. Primers for Phospho1 (Accession number NM204845) (forward 5′CGA GGG CTT CTA CAA TGA G3′; reverse 5′GAA GAG CTC GTG GTT CTT GG3′), and 18S (Accession number M59389) (forward 5′CGG CTA CCA CAT CCA AGG AA3′, reverse 5′GCT GGA ATT ACC GCG GCT3′) were used. Primers for Tnap (Accession number XM423297) were obtained from Primer Design Ltd, Southampton, UK (forward 5′ACT TCC TTT TTT TTT TTT TTT G3′; reverse 5′GTC GGT CTC GTT GTT CCT GTG3′).

**Western blotting analysis**

Cultured cells and developing leg tissue (stages 23-36HH) were lysed in RIPA buffer (20mM Tris-HCl, 135mM NaCl, 10% glycerol, 1% IGEPAL, 0.1% SDS, 0.5% deoxycholic acid, 2mM EDTA) containing “Complete” protease inhibitor cocktail according to manufacturer’s instructions (Roche, East Sussex, UK). Immunoblotting was undertaken as described previously [36]. Nitrocellulose membranes were probed for 1.5h at room temperature with 2 μg IgG/ml sheep-anti-PHOSPHO1 antibody in 5% milk [20], washed in TBST and incubated with anti-sheep/goat IgG-peroxidase (DAKO, Cambridgeshire, UK) for 1.5h (1:2000 dilution in 5% milk). The immune complexes were visualised by enhanced chemiluminescence (ECL) (GE Healthcare, Buckinghamshire, UK). Membranes were washed in ‘stripping buffer’ (Pierce, Rockford, IL, USA) and re-probed for 1h for β-actin expression (1:5000 dilution in 5% milk; anti β-actin clone AC15; Sigma) which acted as a loading control.

*Bone. Author manuscript; available in PMC 2011 April 1.*
Membranes were also probed overnight at 4°C with (i) sheep anti-TNAP antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) (1:500 dilution in 5% BSA), washed in TBST and incubated with anti-sheep/goat IgG-peroxidase (Dako) for 1.5h (1:2000 dilution in 5% milk) and (ii) mouse anti-osteocalcin (Abcam, Cambridge, UK) (1:500 dilution in 5% BSA), washed in TBST and incubated with anti-mouse IgG-peroxidase (Dako) for 1.5h (1:2000 dilution in 5% milk).

**Whole mount alcian blue/alizarin red staining**

Wild-type and talpid³ embryos (36HH and 37HH) were fixed in absolute ethanol for 1 week, and after the skin and viscera were removed the embryos were post-fixed in aceton for 1 week. Embryos were stained in 0.1% alcian blue/0.1% alizarin red/70% ethanol for one week, cleared in 20% glycerol/1%KOH for 3 days then finally cleared in graduated steps of glycerol to 100% glycerol.

**In vivo delivery of lansoprazole**

Embryos at 5 days of development (stages 26-27HH) were windowed and 50μl of 0.1mM lansoprazole/0.1% DMSO was pipetted into the amniotic sac through a small hole made in the amniotic membrane. Embryos were left to develop until 10 days of development. Control embryos were exposed in the same way to 0.1% DMSO only. Embryos were then processed for alcian blue/alizarin red staining as described above.

**Whole-mount in situ hybridisation**

Hybridizations were completed as described by Nieto et al [37], with the variation of using a DMSO permeablization treatment instead of Proteinase K as previously described for embryos older than stage 26HH [21]. Stage 26-35HH embryos were dissected in half so that contralateral limbs could be used for Phospho1 and Tnap localization to allow direct comparison of expression patterns. The following templates and sample numbers were used for each embryo stage: Phospho1 (UMIST ChEST 603413742F1; talpid³ n=3, wild-type n=3); Tnap (UMIST ChEST 603605456F1 talpid³ n=3, wild-type n=3).

**Statistical analysis**

All in vitro experiments were performed at least twice. General Linear Model analysis and the Student’s t-test were used to assess the data. All in vitro data are expressed as the mean +/- S.E.M. of six observations within each experiment. Statistical analysis was performed using Minitab 14. P<0.05 was considered to be significant.

**Results**

**Matrix production and mineral formation in limb bud micromass cultures**

Micromass cultures had negligible staining for either alcian blue or alizarin red immediately after plating (day 0) but staining increased over time in culture with significantly higher staining intensities of both at days 7 and 10 (Figs. 1A, B). Collagen II gene expression was weakly expressed by chondroprogenitors at day 0 but expression was visibly higher from culture day 3 onwards (Fig. 1C). These data confirm that over a 10-day culture period the mesenchymal cells differentiate into chondrocytes with subsequent matrix mineralization. This is in agreement with previous studies [38,39].

**PHOSPHO1 and TNAP expression in cultured micromasses**

Whilst Phospho1 and Tnap mRNA expression were observed at all time points studied (days 0-10) the expression of Phospho1 was significantly higher after 7 (6.1 fold; P<0.05) and 10-days (17 fold; P<0.001) of culture when compared to day 0 cultures whereas significantly
higher levels of expression of Tnap was not observed until after 10-days of culture (3.6 fold; P<0.001) (Figs. 2A, B). Comparable changes in PHOSPHO1 and TNAP protein expression were also observed (Fig. 2E). The double band noted in the PHOSPHO1 western blots represents two alternative transcripts from the Phospho1 gene [23]. These data reveal that higher PHOSPHO1 and TNAP expression is associated with mesenchymal differentiation and matrix mineralization.

**PHOSPHO1 and TNAP expression in developing chick limbs**

In order to extend our observations obtained from the micromass cultures we also analysed Phospho1 and Tnap expression in developing embryonic legs (23–36HH) by qPCR. Analysis of chick leg tissue revealed that collagen II expression was weakly expressed at 23HH but was upregulated from 27HH onwards (Fig. 1D). Phospho1 gene expression increased with developmental age and was significantly higher at 32HH (14.6 fold; P<0.05) and 36HH (22.6 fold; P<0.01) compared to 23HH tissue (Fig. 2C). This was in contrast to Tnap gene expression where a biphasic expression pattern was observed. In comparison to 30HH tissue, expression was significantly higher in both 23HH (P<0.05) and 36HH (P<0.01) tissue (Fig. 2D). Comparable changes in PHOSPHO1 and TNAP protein expression with developmental age were also observed (Fig. 2F).

Expression analysis of Phospho1 and Tnap using whole mount RNA in situ hybridization, correlated with qPCR data. Phospho1 expression was not seen in the developing chick embryo at either stage 23HH or 26HH (Figs. 3A, C). However, Tnap expression was widespread in the embryo, not only confined to cartilage condensations, in both stage 23HH embryos (Fig. 3B) and in contralateral limbs to those used for Phospho1 analysis at stage 26HH (Fig. 3D). In stage 31HH embryos, before the reported appearance of alizarin red staining in the radius, ulna, metacarpals or metatarsals [27] expression of Phospho1 and Tnap expression could be seen superficially in the periosteum of the central diaphysis of the humerus (not shown) radius, ulna and digit 3 metacarpal in the wing (Fig. 3E) and in the femur (not shown),ibia, fibula and metatarsals of digit 2, 3, 4 in the foot (Fig. 3F). When expression patterns of Phospho1 and Tnap were compared in limbs from the same embryo, almost identical patterns were obtained, except that Tnap appeared marginally weaker, particularly in the metatarsals (Fig. 3F). The widespread expression of Tnap throughout mesenchymal tissues at stage 26HH (Fig. 3D) appeared down-regulated except for some residual expression in the foot (31HH; Fig. 3F) which may explain the reduction in overall gene and protein expression noted at 30HH in the qPCR and western blotting studies (Figs. 2D, F). At stage 35HH, expression of Phospho1 and Tnap was seen to be similar in the humerus, radius, ulna, and metacarpals of digits 3 and 4 of the wing (Fig. 3G) and in the femur, tibia, fibula (not shown) and metatarsals of the foot (Fig. 3H). However expression of Tnap appeared marginally advanced of Phospho1 appearing for the first time in the phalanx1 of digit 2 in the foot (Fig. 3H, arrow) which is the next element to become mineralized after the metatarsals at stage 37/38HH [27]. Thus the expression patterns observed in the long bones agree with the data from the micromass cultures and show the existence of a tightly regulated pattern of Phospho1 and Tnap expression which precedes mineralization of the developing limb.

**FGF2 induced inhibition of chondrogenesis and PHOSPHO1 expression**

Mesenchymal cell differentiation is particularly sensitive to the inhibitory effects of fibroblast growth factors (FGFs) and FGF2 specifically has been shown to reduce proteoglycan synthesis in chick limb micromass cultures [40]. Therefore, we next determined if this inhibition of differentiation by FGF2 was associated with altered PHOSPHO1 and TNAP expression and matrix mineralization. In the absence of FGF2, alcian blue staining revealed a continuous sheet of cartilage formed over the culture well whereas in the presence of FGF2, alcian blue staining was lower after 7-days in culture (64%; P<0.001; Fig. 4A) and regions of non-cartilaginous
tissue appeared within the cartilage mass. Similarly, matrix mineralization and collagen deposition were also significantly less by 7-days of FGF2 treatment (17%; P<0.05; Fig. 4B and 23%; P<0.001; Fig. 4C, respectively). FGF2 exposure for 7-days, lowered Phospho1 (~2 fold; P<0.001; Fig. 4D) and Tnap gene expression (~3 fold; P<0.001; Fig. 4E). Comparable reductions in PHOSPHO1 and TNAP protein expression with FGF2 exposure were also observed (Fig. 4F). These data indicate that an inhibition of mesenchymal cell differentiation and subsequent chondrogenesis results in decreased PHOSPHO1 expression and alizarin red staining. These data are supportive of a role for PHOSPHO1 in regulating matrix mineralization.

Effect of PHOSPHO1 inhibition on mineral formation

Having established the expression profile of PHOSPHO1 during chondrogenesis and that inhibition of this process results in reduced PHOSPHO1 expression and matrix mineralization we then determined if the direct inhibition of PHOSPHO1 enzyme activity resulted in the reduced mineralization of micromass cultures. To accomplish this, functional studies utilising lansoprazole, a small-molecule specific inhibitor of PHOSPHO1 [23], were undertaken. Initial studies indicated that although lansoprazole increased LDH accumulation within the culture medium (control: 1.24 +/- 0.21SD relative units/μg protein; lansoprazole: 4.13 +/- 0.25SD relative units/μg protein; P<0.001) cell death was not sufficient to significantly alter micromass protein content (control: 0.18 +/- 0.03SD μg protein; lansoprazole: 0.14 +/- 0.01SD μg protein; NS) nor inhibit chondrocyte terminal differentiation as detected by collagen type X expression (Fig. 5A). This suggests that lansoprazole does not inhibit cell accumulation and that the treated cells are in the correct hypertrophic differentiated state for matrix mineralization to potentially proceed. Exposure of lansoprazole (100μM in 0.1% DMSO) reduced alizarin red staining after 3-day (26%; P<0.05) and 7-day (34%; P<0.05) culture periods (Fig. 5). This reduction in mineralization by lansoprazole is noteworthy as it indicates that endogenous TNAP alone is not sufficient to drive optimal matrix mineralization and is in accord with our hypothesis that both PHOSPHO1 and TNAP are required for mineralization of the skeleton. These in vitro data were confirmed by in-vivo studies, in which exposure of embryos to lansoprazole (100μM in 0.1% DMSO) between 5-10-days of development, reduced or ablated mineralization of the mid-diaphysis of the long bones of both the wing (compare Figs. 6A, B; lansoprazole treated=14/14 had reduced/alblated alizarin red, 3/14 DMSO treated had reduced alizarin red) and leg (compare Figs. 6C & D; lansoprazole treated=13/13 had reduced/alblated alizarin red, 2/14 DMSO treated had reduced alizarin red). Furthermore in many instances it appeared as though there was prolonged expression of alcian blue in the mid-diaphysis of lansoprazole treated embryos. These in vivo studies demonstrate a clear functional role for PHOSPHO1 in chick limb development and mineralization.

Loss of PHOSPHO1 in talpid3 embryos

The functional role for PHOSPHO1 in the mineralization process demonstrated by the inhibitor studies was further suggested by the investigation of Phospho1 expression in talpid3, a chicken mutant with defective endochondral mineralization [41]. Whole mount alcian blue/alizarin red staining at 9-10 days of development confirmed the abnormal mineralization phenotype of the talpid3 mutant. While wild-type long bones of the wing and leg consisted primarily of a cartilaginous matrix with alizarin red staining of mineral restricted to the mid-shaft of the diaphysis (Figs. 7A, C), alizarin red staining was not observed in talpid3 long bones (Figs. 7B, D). Alizarin red staining was, however, observed at sites of membranous ossification such as the clavicle, in both wild-type and talpid3 bones (Figs. 7A, B).

As seen before, expression patterns of Tnap and Phospho1 were similar in contralateral limbs in both the flat bones and the long bones of wings (Figs. 7E, I) and legs (Figs. 7G, K) of wild-type embryos and corresponded to areas of ossification (Figs. 7A, C). In talpid3 embryos,
expression of both \( Tn \) (Figs. 7F, H) and \( \text{Phospho1} \) (Figs. 7J, L) was absent in the long bones of the wing and leg but present in the clavicle (asterix; Figs. 7F, J). The expression of \( \text{Phospho1} \) and \( Tn \) in talpid\(^3\) clavicle was similar to that observed in the corresponding wild-type clavicle (asterix; Figs. 7E, I). Immunoblotting studies revealed that osteocalcin, (a marker of bone formation), was downregulated but still present in talpid\(^3\) long bones compared to wild-type, and unaltered in the talpid\(^3\) clavicle (data not shown). Comparison of \( \text{Phospho1} \) and \( Tn \) expression between the flat and long bones of wild-type and talpid\(^3\) embryos indicates a clear association between PHOSPHO1 and TNAP expression and mineralization of bone.

**Discussion**

The precise biochemical processes regulating matrix mineralization are not yet fully understood. It is still not clear whether, under physiological conditions, mineralization is an active process caused by the presence of promoters of mineralization, or a passive process through a lack of mineralization inhibitors [42]. Along with an optimum balance of both inhibitors and promoters, the mineralization process requires sufficiently high concentrations of \( \text{P}_\text{i} \) for the formation of \textit{de novo} calcium phosphate crystals. It is widely accepted that in bone matrix, TNAP generates \( \text{P}_\text{i} \) for HA crystallization [13,14]. However, it is now clear that the production of \( \text{P}_\text{i} \) for matrix calcification is not entirely attributable to TNAP activity, and that other phosphatases may play a key role in the mineralization process.

\( \text{Akp2} \) knockout mice develop postnatal mineralization defects, including osteomalacia and hypomineralization [9,18]. These abnormalities are likely to be caused by a build up of \( \text{PP}_\text{i} \), a known substrate of TNAP [13] and a potent inhibitor of HA crystal formation [4]. Indeed, hypomineralization is greatly reduced in [\( \text{Akp2}^{+/+} ; \text{Enpp}1^{-/-} \)] double-knockout mice where extracellular \( \text{PP}_\text{i} \) concentrations return to normal with the ablation of NPP1 enzyme activity [7,9]. The elevated extracellular \( \text{PP}_\text{i} \) levels in turn leads to upregulated osteopontin expression by \( \text{Akp2}^{+/+} \) osteoblasts [11]. It has recently been shown that it is the combined accumulation of extracellular \( \text{PP}_\text{i} \) and osteopontin that causes osteomalacia in \( \text{Akp2}^{+/+} \) mice [11].

The location of TNAP to the outer surface of MV membrane, and the role of this enzyme as a pyrophosphatase suggest that other molecules or mechanisms are responsible for increasing intravesicular \( \text{P}_\text{i} \) levels to achieve a \( \text{P}_\text{i}/\text{PP}_\text{i} \) ratio conducive for crystallization. The sodium-dependent phosphate type III transporter Pit-1 [43,44] and other phosphatases known to be present in MVs, including pyrophosphatase, AMPase, and ATPase [45-47] may be involved. Recent work has presented the first functional evidence that PHOSPHO1 is a MV phosphatase involved in skeletal mineralization [23]. The present study extends these previous in \textit{vitro} findings, providing in \textit{vivo} functional evidence of a role for PHOSPHO1 in the initial stages of mineral formation during mesenchymal cell differentiation and embryonic limb bud development.

Chondrogenic differentiation of mesenchymal cells is a prerequisite for cartilage formation in the developing limb, wherein cell proliferation is followed by precartilage condensation, leading to formation of the cartilaginous template for the future skeleton [48-51]. High-density micromass cultures of limb bud mesenchyme are a well-studied and accepted in-vitro model for this process [52]. By exploiting these properties of micromass cultures, we were able to demonstrate a strong relationship between cartilage mineralization and PHOSPHO1 and TNAP expression and this was confirmed in \textit{vivo} by the examination of developing limbs directly dissected from embryos of various ages. Furthermore, in \textit{situ} hybridization studies demonstrated that the \( Tn \) and \( \text{Phospho1} \) gene expression was localized to the mineralized region of the developing bone shaft. Whilst slight differences in \( \text{Phospho1} \) and \( Tn \) expression were noted throughout the period of embryo development studied, these results collectively
reveal a tightly regulated pattern of PHOSPHO1 and TNAP expression that preceeds mineralization of the developing limb.

The effect of PHOSPHO1 inhibition on mineral formation was examined by exposing micromass cultures and developing embryos to lansoprazole. Lansoprazole belongs to a class of compounds known as the 2-(2-pyridylmethylsulfinyl)-1H-benzimidazoles, and is an inhibitor of H+ and K+ (H+/K+)-ATPase of stomach parietal cells. Under acidic conditions, lansoprazole is converted into an acid-activated cationic sulphenamide form (AG2000), which acts as a proton pump inhibitor [53], blocking the final step of acid production. Having demonstrated the reduction in mineral formation in cultured micromasses when exposed to lansoprazole, we established a functional role for PHOSPHO1 in developing chick limbs. This is the first in vivo evidence for a crucial developmental role of PHOSPHO1 in skeletal mineralization. PHOSPHO1, which is sequestered within the lumen of the MV, is likely to increase the intravesicular concentrations of P\textsubscript{i} to allow mineralization to occur [23]. This is likely to occur in synergy with phosphate [43,44] and calcium [54] transporters to facilitate the production of the initial crystals for HA deposition. Whilst the inhibitory effect of lansoprazole on mineral formation suggests that endogenous TNAP alone is not sufficient to drive optimal matrix mineralization we do recognise that lansoprazole has recently been shown to inhibit the ATPase activity of purified PHOSPHO1 by 52.8%, of purified NPP1 by 14.4% and of purified TNAP by 2.4% [55]. We therefore cannot rule out a role for these cross-specificities for related phosphatases in the resulting pathology of the lansoprazole treated chicks.

The functional role for PHOSPHO1 in the mineralization process has been further supported by the loss of PHOSPHO1 expression in FGF2 treated micromass cultures and the long bones of the talpid\textsuperscript{3} chicken mutant. It is recognized that mesenchymal cell populations are particularly sensitive to the inhibitory effects of FGFs [38] and although FGF2 affects many genes during skeletal development the results from the FGF2 treated micromass cultures indicates that the inhibition of chondrogenesis and subsequent matrix mineralization by FGF2 is associated with a marked reduction in PHOSPHO1 expression.

The talpid\textsuperscript{3} mutation is a member of the classical developmental talpid group, so called because their paddle-shaped limbs resemble those of the mole (Talpa). In addition to the limb defects the talpid\textsuperscript{3} mutant, is characterized by an almost bewildering set of malformations including facial, skeletal, and vascular defects [41,56]. It is now clear that all these abnormalities are in regions of the embryo that depend on hedgehog (Hh) signalling [57]. Intriguingly some aspects of the gross phenotype (e.g., polydactylous limbs) suggest a gain of Hh function whereas others (e.g., hypoteleorism in which the eyes are pulled together) suggest a loss of Hh function. The present study has confirmed the abnormal endochondral mineralization phenotype of the talpid\textsuperscript{3} mutant. No mineralization was seen in talpid\textsuperscript{3} long bones at 37HH, whereas mineralization was observed in the flat bones, such as the clavicle. This is in agreement with previous work in the talpid\textsuperscript{3} mutant, which at 37HH reports jaw, furcula, squamosal and clavicle ossification, but no endochondral bone ossification [41].

Our analysis of Phospho1 and Tnap in talpid\textsuperscript{3} embryos represents a unique investigation into the individual contribution of these proteins for mineralization. The absence of Tnap and Phospho1 expression in only the talpid\textsuperscript{3} long bones, and not the flat bones, shows a clear correlation between mineralization and Tnap and Phospho1 gene expression. We do however acknowledge that due to the broad range of pathways targeted by hedgehog signalling it is not possible from this data to directly attribute a role for PHOSPHO1 in the mineralization process. Talpid\textsuperscript{3} embryos have been previously shown to have abnormal TNAP activity, lacking the normal high enzyme activity in the perichondrium and having other areas of unusually high
enzyme activity [56]. The defective TNAP and PHOSPHO1 expression may be a consequence of altered osteoblast differentiation which is known to be influenced by hedgehog signalling.

In conclusion, this study has revealed a strong relationship between cartilage mineralization and PHOSPHO1 and TNAP expression during embryonic limb bud development in the chick. In addition, the inhibition of mineralization through FGF2 exposure, together with functional studies employing the inhibitor lansoprazole have shown that PHOSPHO1 has the ability to modulate skeletal mineralization in-vitro and in-vivo. Furthermore, Phospho1 expression is lost in talpid3, a chicken mutant with defective endochondral mineralization. These data further strengthen the hypothesis that PHOSPHO1 plays a key role in bone mineralization, likely to be linked to the glycerolipid metabolism pathways involving the degradation of phosphatidylethanolamine and phosphatidylcholine and the production of P_i for MV-mediated mineralization.

Acknowledgments

This work was supported by grant AR53102 from the National Institutes of Health, USA and Institute Strategic Programme Grant funding from the Biotechnology and Biological Sciences Research Council, UK. We are grateful to Miss Elaine Seawright for her contribution to the experiments.

References


[54]. Wu LNY, Ishikawa Y, Sauer GR, Genge BR, Mwale F, Mishima H, Wuthier RE. Morphological and biochemical characterization of mineralizing primary cultures of avian growth plate


Fig. 1.
Quantification of (A) alcian blue and (B) alizarin red staining in micromasses derived from stage 23HH limb bud mesenchymal cells, which were cultured for 0, 3, 7 and 10-days. Data are presented as the mean ± S.E.M. of six observations within each time point. ** P<0.01; ***P<0.001. Expression of Collagen type II by PCR in (C) micromass cultures maintained for up to 10-days in culture and (D) chick limb tissue at stages 23-36HH.
Fig. 2.
Fold changes in the mRNA expression of (A, D) Phospho1 and (B, E) Tnap in (A, B) micromasses prepared from stage 23HH limb bud mesenchymal cells and cultured for 0, 3, 7 and 10-days or in (D, E) chick limb tissue at stages 23-36HH. PHOSPHO1 and TNAP protein expression in corresponding (C) micromasses cultured for 0-10d and (F) tissues at 23-36HH. Data are presented as the mean +/- S.E.M. of six observations within each culture time point or of 4 limb buds/limbs of each developmental age. * P<0.05; **P<0.01; ***P<0.001.
Fig. 3.
Whole-mount RNA in-situ hybridization showing *Tnap* and *Phosphol* expression during development. (A) Expression of *Phosphol* at stage 23HH of development. (B) Expression of *Tnap* at stage 23HH of development. (C) Expression of *Phosphol* in the leg at stage 26HH of development. (D) Expression of *Tnap* in the leg at stage 26HH of development. (E) Contralateral wings showing expression of *Phosphol* (left) and *Tnap* (right) at stage 31HH, arrows indicates metacarpal of digit 3. (F) Contralateral legs showing expression of *Phosphol* (left) and *Tnap* (right) at stage 31HH, arrowheads indicate expression in the metatarsals. (G) Contralateral wings showing expression of *Phosphol* (left) and *Tnap* (right)
at stage 35HH. (H) Contralateral legs showing expression of Phospho1 (left) and Tnap (right) at stage 35HH, arrow indicates Tnap expression in phalanx1 of digit 3.
Abbreviations: R=radius, U=ulna, MT=metatarsals.
Fig. 4.
Quantification of (A) alcian blue (B) alizarin red and (C) sirius red staining in 7-day cultured micromasses derived from stage 20 limb bud mesenchymal cells in the presence of FGF2 (50ng/ml). Fold changes in the mRNA expression of (D) Phospho1 and (E) Tnap in 7-day cultured micromasses derived from stage 20 limb bud mesenchymal cells in the presence of FGF2 (50ng/ml). Data are presented as the mean ± S.E.M. of six observations within each treatment. * P<0.05; ***P<0.001 (F) PHOSPHO1 and TNAP protein expression in corresponding 7-day cultured micromasses.
Fig. 5.  
(A) Expression of Collagen type X by PCR in 3 individual control and 7-day lansoprazole treated micromass cultures maintained for up to 10-days in culture. (B) Effect of 3-day and 7-day lansoprazole exposure (100μM) on micromass alizarin red staining. Data are presented as the mean +/- S.E.M. of six observations within each treatment. NS: not significant. * P<0.05; **P<0.01
Fig: 6.
Whole-mount alcian blue/alizarin red staining showing cartilaginous matrix/mineral at 10-days of development following exposure to DMSO (A, C) or lansoprazole (B, D) in the long bones of the wing and leg. In comparison to the mineralization centers of the control limbs (A, C; asterisks) little or no mineralization was noted in the diaphysis of the long bones of lansoprazole treated embryos (B, D; asterisks).
Fig. 7.
Whole-mount alcian blue/alizarin red staining of wild-type (A, C) and talpid3 (B, D) embryos at 10-days of development, clavicles are marked by an asterisk, mineralization of the humerus and femur of wild-type embryos and equivalent regions in talpid3 embryos indicated by arrows. Although the long bones of the mutant talpid3 embryos are poorly formed individual long bones are still clearly seen not to be mineralized which is in contrast to their wild-type counterparts. The clavicle is mineralized in both the wild-type and talpid3 embryos. (E-H) Expression of Tnap in wild-type wing (E; asterisk denotes clavicle), femur (G) and talpid3 wing (F, asterisk denotes clavicle) and femur (H). Figs. I-L. Expression of Phospho1 in wild-type wing (I; asterisk denotes clavicle), femur (K) and talpid3 wing (J, asterisk denotes clavicle) and femur (L).